Epidiolex

Cannabis stocks headed lower Tuesday after a Monday communication from the FDA, which sent warning letters to 13 companies for illegally selling products containing containing cannabidiol (CBD), violating the Federal Food, Drug, and Cosmetic Act. The 15 companies were warned for...

New guidelines issued in the United Kingdom for the consumption and prescription of cannabis issued by the National Institute for Health Care and Excellence fell short of expectations, according to Cantor Fitzgerald.  What Happened The guidelines are an example of the challenges that Canadian...

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) announced Sunday that two of its medicines have been recommended by the U.K.’s National Institute for Health and Care Excellence to receive routine reimbursement from the National Health Service.  What Happened Epidiolex, known as...

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) reported better-than-expected third-quarter revenues, thanks to strong sales of its cannabinoid epilepsy drug Epidiolex. The Analyst Bank of America analyst Tazeen Ahmad reiterated a Buy rating and $218 price target. (See track record here) Cantor...

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) shares are down after the company released its third-quarter earnings report Tuesday afternoon. Third-quarter earnings came in at a loss of 4 cents per share, which may not compare to estimates that called for an 87-cent loss. Sales came in at $90.971...

Cannabinoid-based drug maker GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) CEO Justin Gover told CNBC's Jim Cramer the company's approval to market Epidiolex across Europe is a "historic milestone" for the field of cannabinoid science. European Approval Epidiolex is the only CBD-...

In another milestone, cannabinoid-based drug maker GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) said Monday the European regulatory agency has given the go-ahead for marketing its epilepsy drug Epidiolex in the region. What To Know GW Pharma said the European Commission has approved the marketing...

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH)'s CBD drug Epidiolex, which treats epilepsy, has been deemed too expensive by the U.K.’s National Health Service, according to an iNEWS report. Epidiolex has been shown to be effective in limiting seizures in children...

GW Pharmaceuticals PLC (NASDAQ: GWPH) produces the only cannabis-derived drug approved by the Food and Drug Administration: Epidiolex, for the treatment of seizures in children.  GW is a major pharmaceutical company and shouldn't be grouped together with "sketchy" weed...

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) reported second-quarter earnings and revenue Tuesday that blew past estimates, sending its shares solidly higher Wednesday. The Analysts Morgan Stanley analyst David Lebowitz maintained an Overweight rating on GW Pharma and increased the price...

GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH), the British manufacturer of the CBD drug Epidiolex, said Tuesday that the medication posted net sales of $68.4 million during the quarter and $101.9 million in the first half of 2019.  GW Pharma posted $72 million in revenue in the quarter versus $3.3...

The Food and Drug Administration says it knows there’s demand for cannabis products, but says it's taking a “science-based” approach to determine their safety and efficacy as it considers how to handle their legality. What To Know The FDA recently opened a public docket on...

GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) opened higher by 8 percent Tuesday after posting positive results from its Phase 3 Epidiolex trial and second-quarter earnings beats. Here’s what analysts are saying. Epidiolex Sales GW Pharma closed out its first full quarter of Epidiolex sales...

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH)'s cannabidiol drug Epidiolex is inching closer to another FDA approval.  What Happened GW Pharma reported Monday after the close with positive topline results from a Phase 3 study of Epidiolex in the treatment of seizures associated with...

Zogenix, Inc. (NASDAQ: ZGNX), which develops therapies for rare diseases, said Monday afternoon the FDA issued a refusal to file letter regarding its NDA for Fintepla, chemically fenfluramine hydrochloride, which is being evaluated for the treatment of seizures associated with Dravet syndrome. The...